Atlanta Center for Medical Research

Summary

Atlanta Center for Medical Research is a medical facility located in Atlanta, Georgia. This center is recognized for care of Schizophrenia, Major Depressive Disorder, Depression, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD) and other specialties. Atlanta Center for Medical Research is involved with conducting 219 clinical trials across 145 conditions. There are 3 research doctors associated with this hospital, such as Maria Johnson, MD, Robert Riesenberg, MD, and R RIESENBERG.

Top PIs

Clinical Trials running at Atlanta Center for Medical Research

Bipolar Disorder

Schizophrenia

Sickle Cell Disease

Mania

Bipolar disorder

Depression

Alzheimer's Disease

Coronavirus Infection

I Am A Healthy Volunteer

COVID-19

Azetukalner

for Bipolar Depression

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Recruiting

1 award

Phase 3

3 criteria

Brenipatide

for Bipolar Disorder

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo plus SoC in delaying the worsening of bipolar disorder symptoms. The trial is divided into three periods as follows: Screening period that will last approximately 1 month, treatment period that will last a minimum of 6 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if bipolar symptoms worsen or if withdrawal from the study occurs for any reason.

Recruiting

1 award

Phase 2

1 criteria

Cariprazine

for Bipolar Disorder in Youth

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.

Recruiting

1 award

Phase 3

3 criteria